Sydney, April 14, 2015 - (ABN Newswire) - Organised by the Alliance for Regenerative Medicine (ARM), the 3rd Annual Regenerative Medicine Investor Day was held on March 25th 2015 in New York City.
The one-day investor conference focused exclusively on the regenerative medicine and advanced therapies sector. Regeneus Ltd (ASX:RGS) was one of more than 30 companies that presented during the course of the day.
Below is Regeneus CEO John Martin’s presentation to the group, courtesy of the Alliance for Regenerative Medicine (ARM).
To view the video presentation in New York, please visit: http://www.youtube.com/watch?t=54&v=WGsvzHNEZQA
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient’s cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.
Help employers find you! Check out all the jobs and post your resume.
